EU H2020 Project "APTACHECK (Bioelectronic lab-on-a-chip for point-of-care detection of infectious agents)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/211990/index.html

AptaCheck project word cloud

Explore the words cloud of the AptaCheck project. It provides you a very rough idea of what is the project "AptaCheck" about.

lower 74 samples 15 accurate diagnosis first skills turnover semi 2020 human special consolidated financing clinics equipped automated cutting transfer industry disposable outbreaks gastroenteritis 2024 approved adequately infectious direct clinically complete accuracy wifi optimisation easily detecting diagnostics immediately simplicity obligatory markets clinical departments drawbacks patients 8m observation strategic chip time isolated qr 3bn platform reader overcome secure hospitals groundbreaking action point minutes eventual elisa pathogens scalable aptamer edge wireless biosensor drug data approvals jobs detection portability pcr fast electronic chain identifications lab aptachek enter microbiological later preventing cumulative revenues market linked infections quality manufacturing flu industrial advantage care downstream 600 handling versatile antibody display communication supply mover poc scanner aptacheck biochips beats house parallel instability

Project "AptaCheck" data sheet

The following table provides information about the project.

Coordinator	SOLSTEN DIAGNOSTICS AS Organization address address: HEDEAGER 40 city: AARHUS N postcode: 8200 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Denmark [DK]
Project website	https://solsten-diag.com
Total cost	2˙254˙187 €
EC max contribution	1˙577˙931 € (70%)
Programme	1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing) 2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2017
Duration (year-month-day)	from 2017-08-01 to 2019-07-31

#	participants	country	role	EC contrib. [€]
1	SOLSTEN DIAGNOSTICS AS	DK (AARHUS N)	coordinator	1˙577˙931.00

SOLSTEN DIAGNOSTICS AS

DK (AARHUS N)

coordinator

1˙577˙931.00

Project objective

AptaCheck is a groundbreaking platform for detecting infections pathogens in human samples: the first aptamer-based biosensor platform with lab-quality accuracy, allowing a fast, clinically accurate diagnosis. AptaCheck will overcome the drawbacks of the antibody based point-of-care (POC) devices (lower accuracy and instability). Aptacheck is equipped with a hand-held reader, which comprises a display for direct observation, a QR scanner for identifications, and WiFi for data transfer. AptaCheck beats the state of the art: - Cost: The disposable chip will cost the end user €10 - Time: Turnover-time is less than 15 minutes including sample handling - Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR - Simplicity: No special equipment or skills are needed - Portability: The hand-held reader and biochips can be used at the point of care - Communication: AptaCheck will be linked to electronic lab systems via wireless communication - Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks - Versatile: AptaCheck can easily be adapted to detection of new pathogens. We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips. AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc. With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals. In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.

Deliverables

List of deliverables.
Portfolio of communication material	Other	2020-02-18 15:41:04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "APTACHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "APTACHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)